Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 References  













TSHA-102







Add links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

TSHA-102 is an experimental gene therapy developed by Taysha Gene Therapies for Rett syndrome, delivered via adeno-associated virus serotype 9.[1][2][3][4][5]

References

[edit]
  1. ^ Philippidis, Alex (1 January 2022). "StockWatch: Astellas Hones Gene Therapy Focus with Taysha Stake: Tricida shares crater after failed Phase III trial; Vaxcyte bolsters challenge to Pfizer with clinical success; ESSA triples after acing prostate cancer study". GEN Edge. 4 (1): 809–815. doi:10.1089/genedge.4.1.137. S2CID 253331384.
  • ^ Philippidis, Alex (1 January 2023). "StockWatch: Seven Analysts Cut Price Target for Taysha on FDA Advice, Job Cuts: Gene therapy developer says call for randomized placebo-controlled trial is 'unfeasible'; Evelo falls on clinical miss; HillStream jumps on Dana-Farber deal". GEN Edge. 5 (1): 128–132. doi:10.1089/genedge.5.1.28. S2CID 257006849.
  • ^ Philippidis, Alex (1 October 2020). "Sarepta Duchenne Muscular Dystrophy Candidate Faces U.S. Food and Drug Administration Assay Request, Patent Suit". Human Gene Therapy. 31 (19–20): 1031–1033. doi:10.1089/hum.2020.29137.bfs. PMID 33074027. S2CID 224780854.
  • ^ Philippidis, Alex (1 January 2023). "Taysha Faces Stock Delisting, Scraps $75M Durham Manufacturing Facility: Company aims to preserve capital while anticipating second-half clinical milestones for key programs, with Q1 results expected Thursday". GEN Edge. 5 (1): 362–367. doi:10.1089/genedge.5.1.70. S2CID 258737047.
  • ^ Philippidis, Alex (1 January 2023). "StockWatch: Illumina Results Leave Investors, Analysts Anxious: Taysha zooms on $150M PIPE financing; Alaunos plunges on job cuts; Design nosedives on patient 'reactions'; Phase IIb trial failure sinks Galecto; Zynerba quadruples on up-to-$200M buyout by Harmony". GEN Edge. 5 (1): 549–556. doi:10.1089/genedge.5.1.106. S2CID 265960414.

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=TSHA-102&oldid=1235253108"
    Category: 
    ●Experimental gene therapies
     Hidden categories: 
    ●Articles with short description
     ●Short description with empty Wikidata description
      


    ●This page was last edited on 18 July 2024, at 11:36 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki